Johns Hopkins Cancer Center | Strategic Alliance Partners

February 07, 2022

Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.

January 14, 2022

Christian Frederick Meyer, MD, PhD, MS, discusses standard treatment options in cardiac angiosarcoma.

January 10, 2022

Dr Meyer discusses the rarity of cardiac angiosarcoma, optimizing detection strategies, surgical interventions, and chemotherapy for this patient population, and why immunotherapy has the potential to transform care for patients.

January 05, 2022

Early efficacy data in a phase 1 trial of the agent now known as nivolumab were not enough to convince Julie Brahmer, MD, MSc, about the potential of the investigative agent.

November 04, 2021

Dr. Yarchoan underscores the unique characteristics of fibrolamellar carcinoma, treatment options for these patients, and ongoing research efforts to expand the limited paradigm in this disease.

August 24, 2021

A new era for patients with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia may be on the horizon as investigative efforts aimed away from chemotherapy-based regimens prove efficacious.

August 19, 2021

The discovery of an agent with a unique mechanism of action led investigators to examine sabizabulin, an oral therapy that binds to the colchicine binding site on the microtubule to crosslink α and β tubulin and inhibits microtubule polymerization.

April 10, 2021

Neoadjuvant treatment with nivolumab combined with chemotherapy led to a significant improvement in pathologic complete response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

March 11, 2021

Dr. Levy discusses key research efforts with targeted therapies for patients with lung cancer who harbor NTRK, KRAS, and HER2 aberrations.

February 10, 2021

Julie R. Brahmer, MD, discusses emerging targeted therapies for patients with lung cancer who harbor EGFR exon 20 insertion mutations.

February 05, 2021

Although advances in diagnosis and treatment have led to improvements in overall survival for patients with NSCLC, low rates of survival outcomes are present even in those with nonmetastatic disease.

December 09, 2020

Jerry L​e Pow Spivak, MD, discusses diagnosing essential thrombocythemia.

November 19, 2020

Kristen A. Marrone, MD, discusses research efforts with osimertinib in EGFR-mutated lung cancer, overcoming resistance to the agent, and optimizing sequential molecular testing.

November 16, 2020

Nilofer S. Azad, MD, highlights colorectal cancer treatment and how it has entered an era that is both exciting and challenging.

October 30, 2020

Nilofer S​aba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

October 29, 2020

Nilofer S​aba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.

October 28, 2020

Benjamin P. Levy, MD, discusses the mechanism ​of action of telaglenastat in non–small cell lung cancer.

October 21, 2020

Nilofer S​aba Azad, MD, discusses future research efforts in colorectal cancer.

October 19, 2020

Nilofer S​aba Azad, MD, discusses the significance of germline testing in colorectal cancer.

October 16, 2020

Nilofer S​aba Azad, MD, discusses treatment considerations in right- versus left-sided colorectal cancer.